First-line Herceptin extends progression-free survival in combination with an aromatase inhibitor
Patients with HER2/hormone receptor co-positive tumours have a poor prognosis and are less likely to respond to tamoxifen and, potentially, aromatase inhibitors.1-3
The Phase III TAnDEM trial demonstrated the benefit of combining Herceptin with an aromatase inhibitor (anastrozole) in post-menopausal women with HER2/hormone receptor co-positive disease. Compared with anastrozole alone, the combination tripled the objective response rate (6.8% vs 20.3%, respectively; p=0.018) and doubled progression-free survival.4
Figure 3.2 Significant improvement in progression-free survival with Herceptin plus anastrozole versus anastrozole alone in patients with HER2/hormone receptor co-positive MBC 4 (reproduced by kind permission of the author)
References
- Arpino G et al. Clin Cancer Res 2004; 10: 5670-5676.
- Collins LC, Schnitt SJ. Mod Pathol 2005; 18: 615-620.
- De Placido S et al. Clin Cancer Res 2003; 9: 1039-1046.
- Kaufman B et al. Ann Oncol 2006; 17 (Suppl 9): abs LBA2.
TAnDEM trial
A Phase III, randomised, controlled, open-label study comparing Herceptin plus an aromatase inhibitor (anastrozole) with anastrozole alone as first-line treatment in post-menopausal patients with HER2/hormone receptor co-positive MBC.
|